Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 5kWORD 18k
28 March 2018
Question for written answer E-001930-18
to the Commission
Rule 130
Nicola Caputo (S&D)

 Subject:  Anti-cancer immunostimulating agents
 Answer in writing 

The Stanford University School of Medicine recently conducted studies which provided very promising data on a possible cure for cancer. Specifically, the US scientists demonstrated on an animal (mouse) that the injection of small amounts of two immunostimulating agents (a short stretch of DNA called CpG oligonucleotide and an antibody that binds to OX40 and activates the T cell to lead the charge against the tumorous cells, direct into the solid tumour, thanks to the activation of T lymphocytes) could eliminate all traces of the tumour, even distant metastases.

Can the Commission state, within the limits of its competence:
1. what data it has regarding the above studies and research;
2. if it intends to support future studies on the benefits and potential risks of using these two immunostimulating agents.
Original language of question: IT 
Last updated: 12 April 2018Legal notice